Member Info for Benharper

Still not in post. Is someone working a long notice? Are they struggling to find anyone due to the potentially short tenure? Was whole advert a bit of brinksmanship in Takeover/Licensing discussions?

C5 dosage 250mg/m2

Given the risks you’ve outlined SB I’d say the risk/reward is outstanding at present. The clinical progression of the precision platform appears procedural. At worst a 10% dilution to fund trials until pay dirt is hit. The market may not ever ‘get it’ but there’s plenty of Big Pharma that do. Remember it’s not just Al Smith who’s reputation is as stake when he says the Platform is validated it’s the whole board of Avacta and the clinicians across the Uk and US, would they be continuing with the trial if they were disagreeing with any of the companies statements? Of course there’s the risk of the ‘unknown’ which is why I haven’t sold my house and put it all in, but risk/reward wise this is a great opportunity

Yep I’d like to know the risks too, I’ve some but they’re clean out of Avactas hands. They’ve dealt with a pandemic but there’s always war and asteroid strikes

Today he referred to later in Q4, but yep , anytime of day or night he chooses between now and then is fine by me.

Nowhere have I heard early Jan, complete fabrication

Yep I’d agree, there’s probably a gap to fill, Elliott’s almost certainly waving and the days mdma is looking good

Down Shep, otherwise you’ll be out in the Porch again

Weird isn’t it? Avacta is too risky whereas Boohoo and Purple bricks are fine!

It’s just my favourite theory about what’s going on, it explains the ‘some of C7’ comment. So possibly C6 is running 2-3 more rounds. C7 has commenced and the data from all of P1a is being collated. If and when C6 mimics C5, it’s data and what has happened so far in C7 is tacked on the end then bingo, P1a data readout.

It’s that continuation of treatment I’m referring to BV. Perhaps it’s beyond the 2-3 doses within C5-C6 trial cohorts that clinical responses are seen

LDA, I think the time until P1a data is more about a couple or three more rounds of Ava6000 for the patients on C6 than anything else. If their data and clinical responses mimic or better those in C5 and C4 it’ll add huge weight to the data

Let me guess the IP of Bury FC. Three at the back inverted fullbacks and a false no 9?Northern rock £5 notes at the atm? Monarch Airlines, only piloted by kings and Queens?

Avacta, FAP cleaved chemotherapy without side effects.

Genuinely hilarious FUD.

One question Sheepy, Did any of those examples have paradigm shifting/groundbreaking technologies that were going to transform the delivery of chemotherapy?

Probably all waiting for the lizard king to announce that Elliott is waving so they can all jump back in the pool.

It’s almost as if they’re waiting for a lower buy back price! But they wouldn’t do that though, would they? I reckon we’ll know when they’re back in

Bottmzup and the ascending triangle, sounds like a lewd musical party trick

Nice fud of the fudders gje!

I guess my point is Msponge, is that I don’t think the dynamic will be Avacta going cap in hand to any suitors, I imagine Al and the new BDO be having a few nice lunches in the next few weeks and months.

I’ve been musing on the reasons for the acceleration of P1a data release. If we presume negotiations around licensing/partnerships and even Takeovers/Tx sale are now happening, who does the expedited data readout benefit? Avacta by a mile. If you had any doubts whatsoever in the data you would keep the trial running to the end and publish in April at your big conference, with increasingly large dataset. If you knew you held all the cards you’d publish the data asap to push your suitors to show their hands. Avacta are happy cut deals and are in the driving seat and condensing the time until this happens can only suit them.